Site-Specific Protein Transamination Using N‑Methylpyridinium-4-carboxaldehyde

The controlled attachment of synthetic groups to proteins is important for a number of fields, including therapeutics, where antibody–drug conjugates are an emerging area of biologic medicines. We have previously reported a site-specific protein modification method using a transamination reaction th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Chemical Society 2013-11, Vol.135 (45), p.17223-17229
Hauptverfasser: Witus, Leah S, Netirojjanakul, Chawita, Palla, Kanwal S, Muehl, Ellen M, Weng, Chih-Hisang, Iavarone, Anthony T, Francis, Matthew B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The controlled attachment of synthetic groups to proteins is important for a number of fields, including therapeutics, where antibody–drug conjugates are an emerging area of biologic medicines. We have previously reported a site-specific protein modification method using a transamination reaction that chemoselectively oxidizes the N-terminal amine of a polypeptide chain to a ketone or an aldehyde group. The newly introduced carbonyl can be used for conjugation to a synthetic group in one location through the formation of an oxime or a hydrazone linkage. To expand the scope of this reaction, we have used a combinatorial peptide library screening platform as a method to explore new transamination reagents while simultaneously identifying their optimal N-terminal sequences. N-Methylpyridinium-4-carboxaldehyde benzenesulfonate salt (Rapoport’s salt, RS) was identified as a highly effective transamination reagent when paired with glutamate-terminal peptides and proteins. This finding establishes RS as a transamination reagent that is particularly well suited for antibody modification. Using a known therapeutic antibody, herceptin, it was demonstrated that RS can be used to modify the heavy chains of the wild-type antibody or to modify both the heavy and the light chains after N-terminal sequence mutation to add additional glutamate residues.
ISSN:0002-7863
1520-5126
DOI:10.1021/ja408868a